AT-752 for Dengue

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Atea Study Site, Syracuse, NY
Dengue
AT-752 - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Dengue

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Day 2 until 28 days post virus inoculation

Day 28
Mean quantitative RNAemia (peak and duration and area under the plasma concentration versus time curve [AUC])

Trial Safety

Safety Progress

1 of 3

Other trials for Dengue

Trial Design

2 Treatment Groups

AT-752
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

12 Total Participants · 2 Treatment Groups

Primary Treatment: AT-752 · Has Placebo Group · Phase 1

AT-752
Drug
Experimental Group · 1 Intervention: AT-752 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo Comparator · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 2 until 28 days post virus inoculation
Closest Location: Atea Study Site · Syracuse, NY
Photo of new york 1Photo of new york 2Photo of new york 3
2022First Recorded Clinical Trial
3 TrialsResearching Dengue
11 CompletedClinical Trials

Who is running the clinical trial?

Atea Pharmaceuticals, Inc.Lead Sponsor
18 Previous Clinical Trials
2,197 Total Patients Enrolled
2 Trials studying Dengue
108 Patients Enrolled for Dengue

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to comply with the study requirements and to provide written informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.